This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Today's Health Winners and Losers

Shares of Martek Biosciences (MATK) were among the best-performing health-related stocks Friday, jumping 10% after the maker of nutritional oils said that it landed a 10-year deal to supply oils to Mead Johnson Nutritionals, the U.S.'s biggest producer of infant formula.

Under the deal with Mead Johnson, which is owned by Bristol-Myers Squibb (BMY - Get Report), Martek will serve as exclusive worldwide supplier of DHA and ARA, fatty acids that are used in the production of infant formula. "It's a great day for babies around the world," Martek said. "This agreement illustrates the importance and long-term acceptance of Martek's vegetarian DHA and ARA in infant formula." The company's previous 25-year supply agreement, which was signed in 1992, has been incorporated into the new agreement and remains in effect, Martek said. Shares were trading up $2.20 to $24.14.

Solexa (SLXA) fell 2.7% after the company, which provides genome-sequencing services, filed a shelf registration statement with the Securities and Exchange Commission that would allow it to sell stock, warrants, debt or any combination of the securities for $100 million. Shares were trading down 24 cents to $8.77.

Shares of Illumina (ILMN - Get Report) rose 4% after the company priced 3.5 million shares of stock at $25.50 apiece. The genetics-diagnostics company expects to reap net proceeds of roughly $83.6 million from the offering. The company also granted underwriters an option to buy an additional 525,000 shares to cover over-allotments. The underwriting syndicate is being led by Goldman Sachs and Merrill Lynch. Shares were trading up $1.05 to $26.95.

QLT (QLTI) fell 2% after the company delayed the start of its phase IIa trial of Atrigel, which is being developed for use in patients who suffer from a hormonal disorder called acromegaly, a syndrome characterized by excessive growth of the hands and feet. The decision to delay the trial was made in cooperation with the Food and Drug Administration after adverse events occurred in a primate toxicology study. QLT expects to save about $1 million in 2006 research and development costs because of the delay. The FDA will determine whether patient enrollment can take place after it has a chance to evaluate data from the toxicology study. Shares were trading down 13 cents to $7.51.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BMY $64.50 -1.92%
ILMN $185.64 -1.06%
QLTI $3.91 -0.51%
AAPL $124.43 -1.54%
FB $82.22 -1.18%

Markets

DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs